We validated our finding in multiplatform-omics studies and high-throughput IHC analysis, which raised several important hypotheses on the role of HMGB2 in astrocytoma progression and response to treatment, which are currently being investigated by our group. The gene discussed is HMGB2; the disease is astrocytoma (excluding glioblastoma).